Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

L-021

Supelco

Lorazepam glucuronide solution

100 μg/mL in acetonitrile: water (1:1), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)
Empirical Formula (Hill Notation):
C21H18Cl2N2O8
CAS Number:
32781-79-6
Molecular Weight:
497.28
MDL number:
MFCD02682126
UNSPSC Code:
41116107
PubChem Substance ID:
329817344
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentration

100 μg/mL in acetonitrile: water (1:1)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

O[C@@H]1[C@@H](O)[C@H](OC2N=C(c3ccccc3Cl)c4cc(Cl)ccc4NC2=O)O[C@@H]([C@H]1O)C(O)=O

InChI

1S/C21H18Cl2N2O8/c22-8-5-6-12-10(7-8)13(9-3-1-2-4-11(9)23)25-19(18(29)24-12)33-21-16(28)14(26)15(27)17(32-21)20(30)31/h1-7,14-17,19,21,26-28H,(H,24,29)(H,30,31)/t14-,15-,16+,17-,19?,21-/m0/s1

InChI key

IWOJSSFCRQKNKN-IFBJMGMISA-N

Related Categories

General description

Lorazepam glucuronide is a primary urinary metabolite of lorazepam, a benzodiazepine often prescribed for treatment of anxiety disorders. This Certified Spiking Solution® is suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from clinical toxicology and forensic analysis to urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-901

Lorazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-902

Lorazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

L-907

Lormetazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-911

Lorazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

D-163

Delorazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

L-059

Lorazepam-D4 glucuronide lithium salt solution, 100 μg/mL (Acetonitrile:Water (50:50) (v/v), (as free acid)), certified reference material, ampule of 1 mL, Cerilliant®

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Statements

H225,H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

WGK

WGK 2

Flash Point(F)

55.4 °F

Flash Point(C)

13 °C

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L L von Moltke et al.
Biopharmaceutics & drug disposition, 14(2), 119-130 (1993-03-01)
The effect of probenecid on glucuronidation of acetaminophen and lorazepam in hepatic microsomes from various species was studied to see if in vitro results were consistent with previous in vivo observations. Mouse, rat, and human microsomes were incubated with acetaminophen
Eleonora L Swart et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 45(2), 360-371 (2005-02-03)
The objective is to study the population pharmacokinetics of lorazepam and midazolam in critically ill patients with acute renal failure who are treated with continuous venovenous hemofiltration (CVVH). Twenty critically ill patients with acute renal failure on CVVH therapy were
G Morrison et al.
Clinical pharmacology and therapeutics, 35(5), 646-652 (1984-05-01)
The effect of renal disease on lorazepam kinetics was assessed in three groups: six normal subjects, six patients with renal impairment, and four functionally anephric patients. Subjects received single 1.5- or 3-mg intravenous and oral doses; eight subjects (four normal
Olga Papini et al.
Journal of pharmaceutical and biomedical analysis, 40(2), 397-403 (2005-09-07)
The present study investigates the kinetic disposition with focus on the racemization, glucuronidation capacity and the transplacental transfer of lorazepam in term parturients during labor. The study was conducted on 10 healthy parturients aged 18-37 years with a gestational age
R Verbeeck et al.
British journal of clinical pharmacology, 3(6), 1033-1039 (1976-12-01)
To evaluate the effect of end-stage renal insufficiency and haemodialysis on the elimination of lorazepam, single oral doses of the drug (2.5 mg) were administered to normal subjects and patients with chronic renal failure (CC(r) : less than 2 ml/min)
View All Related Papers

Protocols

UHPLC/MS for Drug Detection in Urine

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service